Ozempic, Wegovy and Rybelsus users pursue compensation for vision loss through semaglutide lawsuits
Did you suffer sudden or unexplained vision loss — such as blurred sight, dimmed vision, or waking up unable to see out of one eye — while taking or shortly after stopping Ozempic, Wegovy, or Rybelsus? These symptoms may be signs of non-arteritic ischemic optic neuropathy (NAION), a serious eye condition now being linked to GLP-1 medications.
NAION occurs when blood flow to the optic nerve is unexpectedly reduced, resulting in partial or total vision loss that often cannot be reversed. Many patients report painless blindness in one eye upon waking, or a sudden loss of peripheral or central vision with no prior warning. Currently, there is no proven treatment to restore vision damaged by NAION.
Individuals who developed NAION after using semaglutide medications may qualify to join the growing GLP-1 multidistrict litigation (MDL) against drug manufacturer Novo Nordisk. If successful, plaintiffs could recover compensation for:
- Medical evaluations and long-term eye care
- Permanent disability or loss of independence
- Lost wages or reduced earning potential
- Pain, suffering and diminished quality of life
Do you qualify?
If you are under the age of 75 and were diagnosed with non-arteritic ischemic optic neuropathy (NAION) while using — or shortly after discontinuing — Ozempic, Wegovy, or Rybelsus, you may be eligible to participate in an Ozempic lawsuit.
To check your eligibility, complete the confidential form on this page.
Fill out the form on this page for more information.
Latest semaglutide lawsuit updates [2025]
Thousands of patients have taken legal action against GLP-1 manufacturer Novo Nordisk, alleging the company failed to warn users about the risks associated with Ozempic, Wegovy, and Rybelsus. These semaglutide lawsuits have been consolidated into a multidistrict litigation (MDL), which continues to grow and move through the legal process. The litigation is called In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation, Case No. 2:24-md-3094, in the U.S. District Court for the Eastern District of Pennsylvania.
Here’s a timeline of key developments in the ongoing Ozempic and semaglutide lawsuits:
September 2025 – The MDL now includes 2,676 pending cases, reflecting rapid growth in legal claims.
December 2024 – The FDA’s year-end report lists 27,656 total adverse events linked to semaglutide medications, with over 10,000 reported in 2024 alone. This includes 386 deaths.
November 2024 – Novo Nordisk updated the Ozempic label to include a warning about the increased risk of pulmonary aspiration. The label still does not include warnings about gastrointestinal and vision loss side effects or NAION. Meanwhile, the master complaint was filed in the semaglutide MDL, which included 1,221 cases at the time.
September 2024 – The MDL grows to 869 cases, showing continued legal activity.
August 2024 – The MDL expands further to 346 cases.
April 2024 – The MDL includes 74 cases, and legal teams were formally appointed to handle consolidated litigation.
February 2024 – The Ozempic MDL was officially established in the Eastern District of Pennsylvania. Cases previously filed in Louisiana were transferred to the Pennsylvania MDL for consolidation.
December 2023 – Nine semaglutide lawsuits were initially consolidated in Louisiana.
August 2023 – The first lawsuit related to Ozempic side effects is filed, marking the start of litigation.
What Ozempic side effects qualify for a lawsuit?
Since being released to the market, semaglutide medications have been linked to a variety of adverse side effects, including gastrointestinal problems, blood clots and hair loss. However, the current GLP-1 litigation primarily focuses on claims involving non-arteritic ischemic optic neuropathy (NAION) — a serious eye condition that can cause sudden and irreversible vision loss.
NAION involves the sudden, painless loss of vision in one or both eyes, often occurring without warning. Many affected individuals report waking up with partial or complete vision loss in one eye. This complication can result in permanent blindness, significantly impacting a person’s quality of life.
What compensation could Ozempic lawsuit plaintiffs receive?
As of September 2025, no settlement has been reached in the Ozempic MDL. However, if the company is found liable for failing to warn users about adverse side effects in one of these semaglutide lawsuits, the plaintiff may be eligible to receive compensation for medical bills, lost wages, pain and suffering, and more. Similar drug injury lawsuits have led to multimillion-dollar payouts.
It is important to note that no outcome is guaranteed, and the amount of compensation may depend on the severity of the injury and the overall impact on the patient’s life.
How to join the Ozempic lawsuit investigation
If you experienced vision loss while taking the GLP-1 Ozempic, Wegovy or Rybelsus and later diagnosed with NAION, you may be eligible to file a semaglutide lawsuit.
To check if you qualify to join the Ozempic MDL, complete the confidential form on this page. A legal representative will review your information and contact you with the next steps.
Fill out the form on this page to see if you qualify for a FREE case evaluation.
See If You Qualify
Join an Ozempic lawsuit investigation
Filling out this form is quick and easy. It only takes a few minutes to see if you qualify.
After you fill out the form, an attorney(s) or their agent(s) may contact you to discuss your legal rights.
ATTORNEY ADVERTISING
The choice of a lawyer is an important decision and should not be based solely on advertisements.
PAID ATTORNEY ADVERTISEMENT: THIS WEB PAGE IS AN ADVERTISEMENT AND THE PARTICIPATING ATTORNEY(S) ARE INCLUDED BECAUSE THEY PAY AN ADVERTISING FEE. Top Class Actions is not a law firm, lawyer referral service, or prepaid legal services plan. We do not endorse or recommend any third-party claims processing company, lawyer, or law firm who participates in the network. We do not make any representation, and have not made any judgment, as to the qualifications, expertise, or credentials of any participating lawyer or processing group. No representation is made that the quality of the legal services or claims processing to be performed is greater than the quality of legal services or claims processing performed by other lawyers or claims processing group. The information contained herein is not legal advice. Any information you submit to Top Class Actions does not create an attorney-client relationship and may not be protected by attorney-client privilege because Top Class Actions is not a law firm. Instead, your information will be forwarded to an attorney(s) or their agent(s) or a claims processing firm for the purpose of a confidential review and potential representation if you qualify. You will only be contacted by an attorney(s) or their agent(s) in response to your inquiry if your initial information appears to qualify you for representation. If you are not contacted by an attorney(s) or their agent(s) within one week, you should consult another firm since all legal claims are subject to filing deadlines. All photos on this website are stock art and do not depict clients.
